Prostate cancer is the second leading cause of death in American men.
Recent advances in the detection of prostate cancer allow treatment of the disease in its early stages, when it is most easily cured. The majority of prostate cancer detected while the malignancy is still within the prostate can be cured. In 1994, Hybritech was the first to receive FDA approval for use of the total PSA test in detecting prostate cancer. Combined, the two detection methods showed an 81 percent increase in cancer detection compared to DRE alone. PSA exists in multiple forms in the blood.